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POLYMERS FOR DELIVERINGA 
SUBSTANCE INTO A CELL 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
0001. This application claims the benefit of priority to 
U.S. Provisional Application No. 61/178,654, filed on May 
15, 2009, which is incorporated by reference herein in its 
entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH ORDEVELOPMENT 
0002. This invention was made with U.S. Government 
support under grant no. CBET 0829128 awarded by the 
National Science Foundation. The government has certain 
rights in the invention. 
BACKGROUND 
0003 Delivery vehicles are often used to delivery a sub 
stance into a cell. Viruses, for example, are effective at deliv 
ering DNA into mammaliancells. However, concerns regard 
ing safety, immunogenicity, repeated dosage, viral 
degradation, and production scale-up have motivated the 
investigation of nonviral approaches for delivering a Sub 
stance into a cell. A variety of nonviral delivery vehicles have 
been discovered. For the delivery of anionic substances or 
Substances that can be made anionic, such as therapeutic 
agents, peptides, polynucleic acids, and the like, cationic 
polymers are particularly useful. For example, cationic poly 
mers can deliver exogenous DNA to cells and enhance the 
efficacy of virus-mediated gene transfer. A few examples of 
known cationic polymers used to deliver genes into cells 
include poly(L-lysine), poly(ethylene imine), chitosan, 
polyamidoamine or PAMAM dendrimers and poly(vinyl pyr 
rolidone). 
0004. Unfortunately, most cationic polymers exhibit high 
cytotoxicities. As a result, alternative delivery vehicles have 
been developed that exhibit lower cytotoxities, such as poly 
mers based on cyclodextrin and carbohydrate comonomers, 
as well as genetically engineered protein-based polymers. To 
date, however, even the alternative delivery vehicles are not 
optimal and are not as effective as viral delivery vehicles in 
vivo. (Glover, D. J.; Lipps, H. J.; Jans, D. A. “Towards safe, 
non-viral therapeutic gene expression in humans.” Nat. Rev. 
Genet. 2005, 6 (4), 299-310.) 
0005 Thus, both the cytotoxicity and the low efficacy of 
nonviral delivery vehicles is a significant limitation in the 
development of safer alternatives to viral delivery vehicles. 
Accordingly, there exists a need for improved nonviral mate 
rials for delivering a substance into a cell that are both effec 
tive and safe. These needs and other needs are addressed by 
the present invention. 
SUMMARY 
0006. In accordance with the purposes of the disclosed 
materials, compounds, compositions, and methods, as 
embodied and broadly described herein, the disclosed subject 
matter, in one aspect, relates to polymers of diglycidylethers 
and amines that are useful for delivering a Substance into a 
cell. In a further aspect, the disclosed subject matter relates to 
pharmaceutical compositions comprising both a polymer and 
a substance to be delivered into a cell. In still a further aspect, 
the disclosed subject matter relates to methods for delivering 
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a Substance into a cell using a polymer or pharmaceutical 
composition. In yet a further aspect, the disclosed subject 
matter relates to methods for treating a disorder by adminis 
tering to a subject a polymer and a substance to be delivered 
into a cell, or by administering to a subject a pharmaceutical 
composition comprising a polymer and a Substance to be 
delivered into a cell. 
0007 Additional advantages will be set forth in part in the 
description that follows, and in part will be obvious from the 
description, or can be learned by practice of the aspects 
described below. It is to be understood that both the foregoing 
general description and the following detailed description are 
exemplary and explanatory only and are not restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0008. The accompanying drawings, which are incorpo 
rated in and constitute a part of this specification, illustrate 
several embodiments of the invention and together with the 
description, serve to explain the principles of the invention. 
0009 FIG. 1a is a reaction scheme employed for the gen 
eration of the library of eighty cationic polymers. FIG.1b is a 
list of the diglycidyl ethers used in the combinatorial matrix 
of the polymer library. FIG. 1c is a list of the amines used in 
the combinatorial matrix of the polymer library. 
0010 FIG. 2 is a three-dimensional bar plot showing 
DNA-binding activity of the diglycidyl ether based cationic 
polymer library determined using the ethidium bromide dis 
placement assay. The percent fluorescence decreased upon 
polymer binding to calf Thymus DNA intercalated with 
Ethidium Bromide was used to measure polymer efficacy. 
0011 FIGS. 3a-care plots demonstrating transfection of 
mammalian cells using polymer leads selected from the DNA 
binding screen (Example 2). Polymer transfection efficacies 
are reported as relative to that of pEI-25. Relative efficacy 
data are plotted on a logarithmic scale (y-axis) and statistical 
significance using p-values was determined by comparing 
data for a given polymer with pBI-25. (3.a) Polymer-mediated 
transfection of PC3-PSMA cells in the absence of serum 
using a polymer: pGL3 plasmid ratio of 25:1 (w/w). (3b) 
Transfection of PC3-PSMA cells in the absence of serum 
using different polymer: plasmid ratios of the 1,4C-1.4 Bis 
polymer. (3.c) Polymer-mediated transfection of PC3-PSMA 
cells in the presence of 10% fetal bovine serum using a 
polymer: pGL3 plasmid ratio of 25:1. (3d) Polymer-mediated 
transfection of murine osteoblasts using 1,4C-1.4 Bis and 
pEI-25 polymers in the presence of 10% fetal bovine serum 
using a polymer pGL3 plasmid ratio of 25:1. 
0012 FIG. 4 is a plot displaying the percentage of dead 
PC3-PSMA cells following polymer/polyplex treatment (Ex 
ample 4). 
0013 FIG. 5a is a plot of polymerization kinetics of 
EGDE-33' and 14C-14Bis polymer formation as reported 
by the disappearance of amines as a function of time. FIG.5b 
is a plot obtained from fourier transform infrared (FTIR) 
spectroscopy of 14C-14 Bis at polymerization at time Oh 
(monomer mixture) and 16 h following initiation of the poly 
mer reaction. 
DETAILED DESCRIPTION 
0014. The materials, compounds, compositions, articles, 
devices, and methods described herein can be understood 
more readily by reference to the following detailed descrip 
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tion of specific aspects of the disclosed subject matter and the 
Examples included therein and to the Figures. 
0015. Before the present materials, compounds, composi 
tions, and methods are disclosed and described, it is to be 
understood that the aspects described below are not limited to 
specific synthetic methods or specific reagents, as such can, 
of course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular aspects 
only and is not intended to be limiting. 
0016. Also, throughout this specification, various publica 
tions are referenced. The disclosures of these publications in 
their entireties are hereby incorporated by reference into this 
application in order to more fully describe the state of the art 
to which the disclosed matter pertains. The references dis 
closed are also individually and specifically incorporated by 
reference herein for the material contained in them that is 
discussed in the sentence in which the reference is relied 
upon. 
0017. In this specification, reference will be made to a 
number of terms, which shall be defined to have the following 
meanings: 
0018. Throughout the description and claims of this speci 
fication the word “comprise' and other forms of the word, 
Such as "comprising” and "comprises.” means including but 
not limited to, and is not intended to exclude, for example, 
other additives, components, integers, or steps. 
0019. As used in the description and the appended claims, 
the singular forms “a,” “an and “the include plural referents 
unless the context clearly dictates otherwise. Thus, for 
example, reference to 'acationic polymer includes mixtures 
of two or more Such cationic polymers, reference to 'a Sub 
stance' includes mixtures of two or more Such substances, 
reference to “a composition' includes mixtures of two or 
more such compositions, and the like. 
0020 Ranges can be expressed hereinas from “about one 
particular value, and/or to “about another particular value. 
When Such a range is expressed, another aspect includes from 
the one particular value and/or to the other particular value. 
Similarly, when values are expressed as approximations, by 
use of the antecedent “about it will be understood that the 
particular value forms another aspect. It will be further under 
stood that the endpoints of each of the ranges are significant 
both in relation to the other endpoint, and independently of 
the other endpoint. It is also understood that there are a 
number of values disclosed herein, and that each value is also 
herein disclosed as “about that particular value in addition to 
the value itself. For example, if the value “10 is disclosed, 
then “about 10' is also disclosed. It is also understood that 
when a value is disclosed that “less than or equal to the value, 
'greater than or equal to the value' and possible ranges 
between values are also disclosed, as appropriately under 
stood by the skilled artisan. For example, if the value “10 is 
disclosed, then “less than or equal to 10” as well as “greater 
than or equal to 10” is also disclosed. It is also understood that 
throughout the application data are provided in a number of 
different formats and that this data represent endpoints and 
starting points and ranges for any combination of the data 
points. For example, if a particular data point “10 and a 
particular data point “15” are disclosed, it is understood that 
greater than, greater than or equal to, less than, less than or 
equal to, and equal to 10 and 15 are considered disclosed as 
well as between 10 and 15. It is also understood that each unit 
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between two particular units are also disclosed. For example, 
if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
0021 References in the specification and concluding 
claims to parts by weight of a particular element or compo 
nent in a composition denotes the weight relationship 
between the element or component and any other elements or 
components in the composition or article for which a part by 
weight is expressed. Thus, in a compound containing 2 parts 
by weight of component X and 5 parts by weight component 
Y,X and Y are presentata weight ratio of 2:5, and are present 
in Such ratio regardless of whether additional components are 
contained in the compound. 
0022. A weight percent (wt.%) of a component, unless 
specifically stated to the contrary, is based on the total weight 
of the formulation or composition in which the component is 
included. 
0023 “Optional or “optionally’ means that the subse 
quently described event or circumstance can or can not occur, 
and that the description includes instances where said eventor 
circumstance occurs and instances where it does not. 
0024. As used herein, the term “substituted” is contem 
plated to include all permissible Substituents of organic com 
pounds. In a broad aspect, the permissible Substituents 
include acyclic and cyclic, branched and unbranched, car 
bocyclic and heterocyclic, and aromatic and nonaromatic 
Substituents of organic compounds. Illustrative Substituents 
include, for example, those described below. The permissible 
Substituents can be one or more and the same or different for 
appropriate organic compounds. For purposes of this disclo 
Sure, the heteroatoms, such as nitrogen, can have hydrogen 
Substituents and/or any permissible Substituents of organic 
compounds described herein which satisfy the valencies of 
the heteroatoms. This disclosure is not intended to be limited 
in any manner by the permissible Substituents of organic 
compounds. Also, the terms “substitution' or “substituted 
with include the implicit proviso that such substitution is in 
accordance with permitted valence of the substituted atom 
and the substituent, and that the substitution results in a stable 
compound, e.g., a compound that does not spontaneously 
undergo transformation Such as by rearrangement, cycliza 
tion, elimination, etc. 
(0025 “A,” and “A” are used hereinas generic symbols to 
represent various specific Substituents. These symbols can be 
any Substituent, not limited to those disclosed herein, and 
when they are defined to be certain substituents in one 
instance, they can, in another instance, be defined as some 
other substituents. 
0026. The term “alkyl as used herein is a branched or 
unbranched saturated hydrocarbon group of 1 to 24 carbon 
atoms, such as methyl, ethyl, n-propyl, isopropyl. n-butyl, 
isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl. 
dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the 
like. The alkyl group can also be substituted or unsubstituted. 
The alkyl group can be substituted with one or more groups 
including, but not limited to, alkyl, halogenated alkyl, alkoxy, 
alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxy 
lic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, 
sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described 
below. 
0027. Throughout the specification “alkyl is generally 
used to refer to both unsubstituted alkyl groups and substi 
tuted alkyl groups; however, Substituted alkyl groups are also 
specifically referred to herein by identifying the specific sub 
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stituent(s) on the alkyl group. For example, the term "halo 
genated alkyl specifically refers to an alkyl group that is 
Substituted with one or more halide, e.g., fluorine, chlorine, 
bromine, or iodine. The term “alkoxyalkyl specifically refers 
to an alkyl group that is substituted with one or more alkoxy 
groups, as described below. The term “alkylamino” specifi 
cally refers to an alkyl group that is substituted with one or 
more amino groups, as described below, and the like. When 
“alkyl is used in one instance and a specific term Such as 
“alkylalcohol is used in another, it is not meant to imply that 
the term “alkyl does not also refer to specific terms such as 
“alkylalcohol and the like. 
0028. This practice is also used for other groups described 
herein. That is, while a term such as “cycloalkyl refers to 
both unsubstituted and substituted cycloalkyl moieties, the 
substituted moieties can, in addition, be specifically identified 
herein; for example, a particular Substituted cycloalkyl can be 
referred to as, e.g., an “alkylcycloalkyl.” Similarly, a substi 
tuted alkoxy can be specifically referred to as, e.g., a "halo 
genated alkoxy, a particular Substituted alkenyl can be, e.g., 
an “alkenylalcohol and the like. Again, the practice of using 
a general term, such as “cycloalkyl and a specific term, Such 
as “alkylcycloalkyl is not meant to imply that the general 
term does not also include the specific term. 
0029. The term “alkoxy” as used herein is an alkyl group 
bound through a single, terminal ether linkage; that is, an 
“alkoxy” group can be defined as —OA' where A' is alkyl as 
defined above. 
0030 The term alkoxylalkyl as used herein is an alkyl 
group that contains an alkoxy Substituent and can be defined 
as -A'-O-A, where A' and A are alkyl groups. 
0031. The term “alkenyl as used herein is a hydrocarbon 
group of from 2 to 24 carbon atoms with a structural formula 
containing at least one carbon-carbon double bond. Asym 
metric structures such as (AA)C=C(AA) are intended to 
include both the E and Z isomers. This can be presumed in 
structural formulae herein wherein an asymmetric alkene is 
present, or it can be explicitly indicated by the bond symbol 
C=C. The alkenyl group can be substituted with one or more 
groups including, but not limited to, alkyl, halogenated alkyl, 
alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, 
carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, 
silyl, Sulfo-oxo, Sulfonyl, Sulfone, Sulfoxide, or thiol, as 
described below. 
0032. The term “alkynyl as used herein is a hydrocarbon 
group of 2 to 24 carbon atoms with a structural formula 
containing at least one carbon-carbon triple bond. The alky 
nyl group can be substituted with one or more groups includ 
ing, but not limited to, alkyl, halogenated alkyl, alkoxy, alk 
enyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic 
acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, Sulfo 
oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below. 
0033. The term “aryl as used herein is a group that con 
tains any carbon-based aromatic group including, but not 
limited to, benzene, naphthalene, phenyl, biphenyl, phenoxy 
benzene, and the like. The term “aryl also includes “het 
eroaryl, which is defined as a group that contains an aromatic 
group that has at least one heteroatom incorporated within the 
ring of the aromatic group. Examples of heteroatoms include, 
but are not limited to, nitrogen, oxygen, Sulfur, and phospho 
rus. Likewise, the term “non-heteroaryl, which is also 
included in the term “aryl. defines a group that contains an 
aromatic group that does not contain a heteroatom. The aryl 
group can be substituted or unsubstituted. The aryl group can 
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be substituted with one or more groups including, but not 
limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, 
aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, 
ether, halide, hydroxy, ketone, nitro, silyl, Sulfo-oxo, Sulfo 
nyl, sulfone, sulfoxide, or thiol as described herein. The term 
“biaryl is a specific type of aryl group and is included in the 
definition of aryl. Biaryl refers to two aryl groups that are 
bound together via a fused ring structure, as in naphthalene, or 
are attached via one or more carbon-carbon bonds, as in 
biphenyl. 
0034. The term “cycloalkyl as used herein is a non-aro 
matic carbon-based ring composed of at least three carbon 
atoms. Examples of cycloalkyl groups include, but are not 
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 
etc. The term "heterocycloalkyl is a cycloalkyl group as 
defined above where at least one of the carbon atoms of the 
ring is substituted with a heteroatom such as, but not limited 
to, nitrogen, oxygen, Sulfur, or phosphorus. The cycloalkyl 
group and heterocycloalkyl group can be substituted or 
unsubstituted. The cycloalkyl group and heterocycloalkyl 
group can be substituted with one or more groups including, 
but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, het 
eroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, 
hydroxy, ketone, nitro, silyl, Sulfo-oxo, Sulfonyl, Sulfone, 
sulfoxide, or thiol as described herein. 
0035. The term "cycloalkenyl as used herein is a non 
aromatic carbon-based ring composed of at least three carbon 
atoms and containing at least one double bound, i.e., C=C. 
Examples of cycloalkenyl groups include, but are not limited 
to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopenta 
dienyl, cyclohexenyl, cyclohexadienyl, and the like. The term 
"heterocycloalkenyl is a type of cycloalkenyl group as 
defined above, and is included within the meaning of the term 
“cycloalkenyl, where at least one of the carbon atoms of the 
ring is substituted with a heteroatom such as, but not limited 
to, nitrogen, oxygen, Sulfur, or phosphorus. The cycloalkenyl 
group and heterocycloalkenyl group can be substituted or 
unsubstituted. The cycloalkenyl group and heterocycloalk 
enyl group can be substituted with one or more groups includ 
ing, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, 
heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, 
halide, hydroxy, ketone, nitro, silyl, Sulfo-oxo, Sulfonyl, Sul 
fone, sulfoxide, or thiol as described herein. 
0036. The term “cyclic group' is used herein to refer to 
either aryl groups, non-aryl groups (i.e., cycloalkyl, hetero 
cycloalkyl, cycloalkenyl, and heterocycloalkenyl groups), or 
both. Cyclic groups have one or more ring systems that can be 
Substituted or unsubstituted. A cyclic group can contain one 
or more aryl groups, one or more non-aryl groups, or one or 
more aryl groups and one or more non-aryl groups. 
0037. The term “aldehyde' as used herein is represented 
by the formula —C(O)H. Throughout this specification 
“C(O) is a short hand notation for C=O. 
0038. The terms “amine' or “amino” as used herein are 
represented by the formula NAAA, where A, A, and A 
can be, independently, hydrogen, an alkyl, halogenated alkyl, 
alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, 
heterocycloalkyl, or heterocycloalkenyl group described 
above. 
0039. The term “carboxylic acid as used herein is repre 
sented by the formula —C(O)OH. A “carboxylate” as used 
herein is represented by the formula—C(O)O. 
0040. The term “ester as used herein is represented by the 
formula —OC(O)A' or C(O)OA', where A' can be an 
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alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, 
cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocy 
cloalkenyl group described above. 
0041. The term “ether as used herein is represented by the 
formula A'OA, where A' and A can be, independently, an 
alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, 
cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocy 
cloalkenyl group described above. 
0042. The term “ketone' as used herein is represented by 
the formula A'C(O)A, where A' and A can be, indepen 
dently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, 
heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or 
heterocycloalkenyl group described above. 
0043. The term “halideas used herein refers to the halo 
gens fluorine, chlorine, bromine, and iodine. 
0044) The term “hydroxyl as used herein is represented 
by the formula —OH. 
0045. The term "nitro” as used herein is represented by the 
formula - NO. 
0046. The term “silyl as used herein is represented by the 
formula—SiAAA, where A, A, and Acan be, indepen 
dently, hydrogen, alkyl, halogenated alkyl, alkoxy, alkenyl, 
alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocy 
cloalkyl, or heterocycloalkenyl group described above. 
0047. The term "sulfo-oxo' as used herein is represented 
by the formulas S(O)A', S(O)A', OS(O)A", or 
—OS(O).OA', where A' can be hydrogen, an alkyl, haloge 
nated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, 
cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group 
described above. Throughout this specification “S(O) is a 
short hand notation for S=O. 
0048. The term “sulfonyl' is used herein to refer to the 
Sulfo-oxo group represented by the formula —S(O).A', 
where A' can be hydrogen, an alkyl, halogenated alkyl, alk 
enyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, het 
erocycloalkyl, or heterocycloalkenyl group described above. 
0049. The term “sulfonylamino” or “sulfonamide' as used 
herein is represented by the formula—S(O)NH-. 
0050. The term “sulfone' as used herein is represented by 
the formula A'S(O)2A, where A' and A can be, indepen 
dently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, 
heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or 
heterocycloalkenyl group described above. 
0051. The term “sulfoxide’ as used herein is represented 
by the formula A'S(O)A, where A' and A can be, indepen 
dently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, 
heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or 
heterocycloalkenyl group described above. 
0052. The term “thiol” as used herein is represented by the 
formula—SH. 
0053 “R',” “R” “R” “R”,” where n is an integer, as used 
hereincan, independently, possess one or more of the groups 
listed above. For example, if R is a straight chain alkyl group, 
one of the hydrogen atoms of the alkyl group can optionally 
be substituted with a hydroxyl group, an alkoxy group, an 
alkyl group, a halide, and the like. Depending upon the groups 
that are selected, a first group can be incorporated within 
second group or, alternatively, the first group can be pendant 
(i.e., attached) to the second group. For example, with the 
phrase “an alkyl group comprising an amino group, the 
amino group can be incorporated within the backbone of the 
alkyl group. Alternatively, the amino group can be attached to 
the backbone of the alkyl group. The nature of the group(s) 
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that is (are) selected will determine if the first group is embed 
ded or attached to the second group. 
0054 The terms “nucleic acid.” “polynucleic acid, and 
"polynucleotide, as used herein, refer to a polymer compris 
ing at least two residues of a nucleotide, which can include 
any N-glycoside or C-glycoside of a purine or pyrimidine 
base or of a modified purine or pyrimidine base, which 
includes those bases that do not occur naturally. Specific 
examples of Such polymers include without limitation any 
form of ribonucleic acid (RNA), deoxyribonucleic acid 
(DNA), genomic DNA, messenger RNA (mRNA), comple 
mentary DNA (cDNA), antisense RNA (aRNA), a synthetic 
nucleic acid polymer, or a mixture thereof, among others. 
0055. Unless stated to the contrary, a formula with chemi 
cal bonds shown only as solid lines and not as wedges or 
dashed lines contemplates each possible isomer, e.g., each 
enantiomer and diastereomer, and a mixture of isomers, such 
as a racemic or scalemic mixture. 
0056 Certain materials, compounds, compositions, and 
components disclosed herein can be obtained commercially 
or readily synthesized using techniques generally known to 
those of skill in the art. For example, the starting materials and 
reagents used in preparing the disclosed compounds and 
compositions are either available from commercial Suppliers 
such as Aldrich Chemical Co., (Milwaukee, Wis.). Acros 
Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh, 
Pa.), or Sigma (St. Louis, Mo.) or are prepared by methods 
known to those skilled in the art following procedures set 
forth in references such as Fieser and Fieser’s Reagents for 
Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 
1991); Rodd's Chemistry of Carbon Compounds, Volumes 
1-5 and Supplementals (Elsevier Science Publishers, 1989); 
Organic Reactions, Volumes 1-40 (John Wiley and Sons, 
1991); March's Advanced Organic Chemistry, (John Wiley 
and Sons, 4th Edition); and Larock's Comprehensive Organic 
Transformations (VCH Publishers Inc., 1989). 
0057 Reference will now be made in detail to specific 
aspects of the disclosed materials, compounds, compositions, 
articles, and methods, examples of which are illustrated in the 
accompanying Examples and Figures. 
0.058 As briefly discussed above, the disclosed subject 
matter, in one aspect, relates to polymers that are useful for 
delivering a Substance into a cell. The disclosed polymers are 
both effective at delivering substances into a cell and safe (i.e., not undesirably cytotoxic). 
0059 Polymers 
0060 Generally, the disclosed polymers are polymers of 
diepoxide and an amine. Such as a diamine. The polymers are 
generally branched at one or more points on the polymer 
backbone. The amines of the polymers allow the polymers to 
be made cationic by Subjecting the polymers to acid. Thus, by 
reference to “polymers' herein, the cationic forms are also 
contemplated. The cationic forms of the polymers can then 
bind to a variety of substances that can be delivered into a cell. 
0061. With reference to FIG. 1a, in one aspect, the poly 
mers disclosed hereinare polymers of amines and diepoxides, 
wherein the amine is represented by the formula: 
NRI 
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and wherein the diepoxide is represented by a formula: 
v-y 
wherein R' and R is independently optionally substituted 
alkyl, optionally substituted cycloalkyl, optionally Substi 
tuted heteroalkyl, optionally substituted heterocycloalkyl, 
optionally substituted aryl, optionally substituted heteroaryl, 
or a combination thereof. 
0062. In specific aspects, R' is optionally substituted alkyl 
or heteroalkyl. Such as aminoalkyl. Specific examples of 
amines, showing suitable variations in R', are shown in FIG. 1c. In other specific aspects, R is optionally substituted alkyl, 
optionally Substituted heteroalkyl. Such as ethylene glycolor 
polyethylene glycol, optionally Substituted cycloalkyl, or 
optionally substituted heterocycloalkyl. Specific examples of 
epoxides, showing suitable variations in R, are shown in 
FIG 1b. 
0063. The polymers are prepared from monomers having 
two or more reactive functionalities, namely epoxides and 
amines, and thus ultimately have a variety of structures that 
are generally branched, have one or more amines, including 
secondary and tertiary amines in the polymer backbone and 
primary amines as end groups, one or more secondary alco 
hols (from the ring-opening of the epoxide), and/or one or 
more epoxides as endgroups. 
0064. With reference to FIG. 1a, the polymers are pre 
pared by reacting the amine with the diepoxide, which 
induces a polymerization sequence, Such as the exemplary 
sequence shown in FIG. 1a, wherein either an amine end 
group in a growing chain reacts with another monomeric 
diglycidyl either, or a monomeric amine reacts with a glycidyl 
ether endgroup, or both. The ratio of amines, glycidyl ethers, 
and alcohols in the backbone can be modulated by the sto 
ichiometric ratio of the monomers. The molecular weight and 
structure of the polymer can be likewise modulated by not 
only the monomer ratio but also by polymerization condi 
tions, such as temperature or duration. 
0065. In practice, the polymers can be made by reacting 
the monomers in solution or neat. When it is desired to form 
cationic polymers from the polymers, acid can be added to the 
polymers to protonate one or more amines of the polymer. If 
the polymer is in Solution, only a slight pH modification is 
needed. Lowering the pH to about 7.4, for example, from a 
more basic starting point, using acid will Suffice to protonate 
a sufficient number of amines. 
0066. With reference to FIG. 1b and FIG. 1c, specific 
examples of the disclosed polymers include polymers pro 
duced from any combination of monomers 1 through 8 and 
monomers A-J, including copolymers 1 (i) A, 1 (i) B. 1 (i) C. 
1(i) D, 1 (i) E, 1 (i) F, 1(i) G, 1(i) H, 1 (i) I, 1 (i) J: 1 (ii) A, 1(ii) 
B, 1(ii) C, 1(ii) D, 1(ii) E, 1 (ii) F, 1(ii) G, 1(ii) H, 1(ii) I, 1(ii) 
J; 2A, 2B, 2C, 2D, 2E, 2F, 2G, 2H, 2I, 2J: 3A, 3B, 3C, 3D, 3E, 
3F, 3G, 3H, 3I, 3J; 4(i)A, 4(i)B, 4(i)C, 4(i)D, 4(i)E, 4(i)F, 
4.(i)G, 4(i)H, 4(i)I, 4(i)J; 4(ii)A, 4(ii)B, 4(ii)C, 4(ii)D, 4(ii)E, 
4(ii)F, 4(ii)G, 4(ii)H, 4(ii)I, 4(ii).J; 5A, 5B, 5C, 5D, 5E, 5F 
5G, 5H,5I,5J; 6A, 6B, 6C, 6D, 6E, 6F, 6G, 6H, 6I, 6J; 7A,7B, 
7C, 7D, 7E, 7F, 7G, 7H, 7I, 7J; 8A, 8B, 8C, 8D, 8E, 8F, 8G, 
8H, 8I, 8J, and combinations thereof. In a specific aspect, the 
polymer is poly(ethyleneglycol diglycidyl ether)-co-(3,3'-di 
amino-N-methyl dipropylamine) or poly(1,4-cyclohex 
anedimethanol diglycidyl ether)-co-1,4-bis(3-aminopropyl) 
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piperazine. In one aspect, the polymer is not 1 (i) A, 1 (i) B, 
1(i) C, 1 (i) D, 1 (i) E, 1 (i) F. 1 (i) G, 1 (i) H, 1 (i) I, 1 (i) J. In 
another aspect, the polymer is not 4(i)A, 4(i)B, 4(1)C, 4(1)D. 
4.(i)E, 4(i)F, 4(i)G, 4(i)H, 4(i)I, 4(1).J. 
0067. The disclosed polymers can have a number average 
molecular weight (Mn) of from about 1 to about 20 kDa, 
including for example, 1, 2, 3, 4, 10, 15, or 18. The disclosed 
polymers can have a weight average molecular weight (Mw) 
of from about 10 to about 50 kDa, including for example, 15, 
20, 23, 26, 30, 35, 40, or 45. The polydispersity (Mw/Mn) of 
the disclosed polymers can be from about 2 to about 7, includ 
ing for example, about 3, 4 or 6. 
0068. The polymers can be tested to evaluate their useful 
ness as delivery agents for Substances to be delivered into a 
cell using screening techniques known in the art. For 
example, to evaluate the usefulness of the polymers in deliv 
ering an anionic polynucleic acid. Such as DNA, into a cell, 
DNA-binding efficacies of the polymers can be determined 
using the ethidium bromide displacement assay, discussed 
below. In vitro and/or in vivo evalutation of the polymers can 
be likewise evaluated by any method known in the art. 
0069 Contemplated uses of the polymers include deliver 
ing a variety of Substances into a cell. As noted above, the 
disclosed polymers and their cationic forms can form an 
association with a substance that has an affinity therefore, and 
as Such can function as a delivery vehicle for delivering the 
Substance into a cell. A variety of drugs, bioactive agents, 
biomolecules, such as peptides, proteins, nucleic acids, poly 
nucleic acids, polynucleotides, among others, which associ 
ate or can be caused to associate with a disclosed cationic 
polymer, can be delivered into a cell. Peptides and proteins 
include any polymer of at least two residues of a natural or 
non-natural amino acid. 
0070. In one aspect, the disclosed polymers can be used in 
transfection procedures. Accordingly, the disclosed polymers 
can be used to facilitate the intercellular delivery of DNA or 
RNA sequences, for example, sequences coding for therapeu 
tically active polypeptides. The disclosed polymers can also 
be used to deliver a primer, promoter, TAG, or siRNA to a cell. 
Likewise, disclosed polymers can be similarly used for the 
delivery of an expressed gene product, such as the polypep 
tide or protein itself. Thus, polymer-mediated delivery of 
DNA and RNA polynucleotides or proteins can provide 
therapy for genetic diseases by interfering with known 
sequences or cellular activities, or by Supplying deficient or 
absent gene products to treat any genetic disease in which the 
defective gene or its product has been identified. The poly 
mer-mediated intracellular delivery described above can also 
provide immunizing polypeptides to the cell, for example, by 
delivering a polynucleotide coding for the immunogen, or by 
delivering the immunogen itself. 
0071. Other therapeutically important nucleic acids suit 
able for polymer-mediated delivery are negatively charged 
oligonucleotides including antisense polynucleotide 
sequences, useful in eliminating or reducing the production of 
a gene product, as described by Tso, P. et al. Annals New York 
Acad. Sci.570:220-241 (1987). Also disclosed is the delivery, 
by means of the polymer, of ribozymes, or catalytic RNA 
species, for example, the “hairpin' type as described by 
Hampel et al. Nucleic Acids Research 18(2):299-304 (1990); 
or the “Hammerhead' type described by Cech. T. and Bass, B. 
Annual Rev. Biochem. 55:599-629 (1986). These antisense 
nucleic acids or ribozymes can be expressed (replicated) in 
the transfected cells. The DNA sequences delivered can be 
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those sequences that do not integrate into the genome of the 
host cell or those that do integrate into the genome of the host. 
These can be non-replicating DNA sequences, or specific 
replicating sequences genetically engineered to lack the 
genome-integration ability. 
0072. When the nucleic acid to be delivered is mRNA, it 
can be readily prepared from the corresponding DNA in vitro. 
For example, conventional techniques utilize phage RNA 
polymerases SP6, T3, or T7 to prepare mRNA from DNA 
templates in the presence of the individual ribonucleoside 
triphosphates. An appropriate phage promoter, such as T7 
origin of replication site is placed in the template DNA imme 
diately upstream of the gene to be transcribed. Systems uti 
lizing T7 in this manner are well known, and are described in 
the literature, e.g., in Current Protocols in Molecular Biology, 
S3.8 (vol. 1, 1988). 
0073. In addition, disclosed herein is the delivery of 
mRNA that is chemically blocked at the 5' and/or 3' end to 
prevent access by RNase (this enzyme is an exonuclease and 
therefore does not cleave RNA in the middle of the chain). 
Such chemical blockage can Substantially lengthen the half 
life of the RNA in vivo. By adding a group with sufficient bulk 
to the RNA, access to the chemically modified RNA by 
RNASE can be prevented. 
0074. Other therapeutic uses of the polymers include the 
delivery of nucleoside or nucleotide analogues having an 
antiviral effect, such as dideoxynucleotides, didehydronucle 
otides, nucleoside or nucleotide analogues having halo-Sub 
stituted purine or pyrimidine rings such as 5-trifluoromethyl 
2-deoxyuridine or 5-flurouracil; nucleoside or nucleotide 
analogues having halo- and azido-substituted ribose moi 
eties, such as 3’-azido-3'deoxythymidine (AZT), nucleoside 
analogues having carbon Substituted for oxygen in the ribose 
moiety (carbocyclic nucleosides), or nucleotide analogues 
having an acyclic pentose such as acyclovir or gancyclovir 
(DHPG). The antiviral potency of these analogues is found to 
be increased when they are presented to the cells as phospho 
lipid derivatives. Effective antiviral lipid derivatives of 
nucleoside analogues comprise phosphatidyl 2',3'-dideoxy 
nucleosides, 2',3'-didehydronucleosides, 3-azido-2-deoxy 
nucleosides, 3-fluorodeosynucleosides and 3'-fluo 
rodideoxynucleosides, 9-3-D-arabinofuranosyladenine 
(araA), 1-B-D-arabinofuranosylcytidine (araC), nucleosides 
Such as acyclovir and gancyclovir having an acyclic ribose 
group, or the same nucleoside analogues as diphosphate dig 
lyceride derivatives. 
0075 Among other therapeutically important agents that 
can be delivered are peptides comprising physiologic species 
Such as interleukin-2, tumor necrosis factor, tissue plasmino 
gen activator, factor VIII, erythropoietin, growth factors such 
as epidermal growth factor, growth hormone releasing factor, 
neural growth factor, and hormones such as tissue insulin, 
calcitonin, and human growth hormone as well as toxic pep 
tides such as ricin, diphtheria toxin, or cobra Venom factor, 
capable of eliminating diseased or malignant cells. 
0076 Use of the disclosed polymers is also contemplated 
for the intra-cellular delivery of various other agents accord 
ing to methods known to those skilled in the art, for example 
as described in Duzgunes, N., Subcellular Biochemistry 
11:195-286 (1985). Materials to be delivered can be proteins 
or polypeptides, as discussed above, or other negatively 
charged molecules, monoclonal antibodies, RNA-stabilizing 
factors and other transcription and translation regulating fac 
tors, antisense oligonucleotides, ribozymes, and any mol 
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ecule possessing intracellular activity that can also associate 
with or becaused to associate with a disclosed cationic poly 
mer. Polymer-mediated delivery further protects the 
described agents from non-productive sequestration by Sub 
stances of the extracellular environment. 
(0077. The delivery procedures described herein can be 
carried out in vitro, in Vivo, or ex vivo. Thus, a polymer and a 
substance to be delivered into a cell can be administered 
directly into a subject, as will be discussed below. Alterna 
tively, a cell can be treated with a polymer and a Substance to 
be delivered into the cell, followed by introducing the treated 
cell into a subject to thereby treat a disorder. In another 
alternative, a cell of a living organism can be removed from 
the organism, treated with a polymer and a Substance to be 
delivered into the cell, followed by reintroduction of the 
treated cell into the organism to thereby treat a disorder. 
0078. In one aspect, the polymer and/or the substance to be 
delivered into the cell can be present in a pharmaceutical 
composition. Local or systemic delivery of the Substance can 
be achieved by administration comprising application or 
insertion of the pharmaceutical composition into body cavi 
ties, inhalation or insufflation of an aerosol, or by parenteral 
introduction, comprising intramuscular, intravenous, intrad 
ermal, peritoneal, Subcutaneous and topical administration. 
The nucleic acids, for example, can be delivered to the inter 
Stitial space of tissues of the animal body, including those of 
muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, 
heart, lymph, blood, bone, cartilage, pancreas, kidney, gall 
bladder, stomach, intestine, testis, ovary, uterus, rectum, ner 
Vous system, eye, gland, and connective tissue. Interstitial 
space of the tissues comprises the intercellular, fluid, muco 
polysaccharide matrix among the reticular fibers of organ 
tissues, elastic fibers in the walls of vessels or chambers, 
collagen fibers of fibrous tissues, or that same matrix within 
connective tissue ensheathing muscle cells or in the lacunae 
of bone. It is similarly the space occupied by the plasma of the 
circulation and the lymph fluid of the lymphatic channels. 
The effect of the polymers in these pharmaceutical composi 
tions is to enhance the potency and efficiency of the therapeu 
tic agent contained therein by facilitating its intracellular 
delivery. 
0079. In all of the nucleic acid delivery strategies dis 
closed herein, an effective DNA or mRNA dosage will gen 
erally be in the range of from about 0.02 ug/kg to about 100 
mg/kg, usually about 0.005-5 mg/kg. However, as will be 
appreciated, this dosage will vary in a manner apparent to 
those of skill in the art according to, e.g., the activity of the 
peptide coded for by the nucleic acid. 
0080 Topical formulations are those advantageously 
applied to the skin or mucosa. Target mucosa can be that of the 
gastrointestinal tract, comprising the mouth, naso-pharynx 
and stomach. Other target tissues can be the accessible Sur 
faces and canal of the ear and the ocular tissues. Polymers 
present in topical formulations can act to facilitate introduc 
tion of bioactive molecules into the target tissue. Such as the 
stratum corneum of the skin, by perturbing the barrier prop 
erties of the protective membrane, or by introducing perturb 
ing agents or penetration enhancers such as AZOneTM or by 
promoting the activity of these penetration enhancers. They 
can also be delivered into muscle or skin using a vaccine gun. 
I0081. Other topical compositions comprising the poly 
mers are preparations comprising topical antibiotics Such as 
clindamycin, tobramycin, neomycin, gentamycin, tetracy 
cline, erythromycin; oxidants such as benzoyl peroxide, anti 
US 2012/0196923 A1 
fungal agents, such as clotrimazole, miconazole, nystatin, 
lactoconzole, econazole, and tolnaftate; retinoic acid for the 
treatment of herpes simplex and comprising antiviral nucleo 
side analogues such as acyclovir and gancyclovir. 
0082. Other formulations comprising the disclosed poly 
mers are topical preparations containing an anesthetic or 
cytostatic agent, immunomodulators, bioactive peptides or 
oligonucleotides, Sunscreens or cosmetics. Preparations for 
topical use are conveniently prepared with hydrophilic and 
hydrophobic bases in the form of creams, lotions, ointments 
or gels; alternatively, the preparation can be in the form of a 
liquid that is sprayed on the skin. The effect of the cationic 
polymers is to facilitate the penetration of the active antiviral 
agent through the stratum corneum of the dermis. 
0083. Similar preparations for ophthalmic use are those in 
which the pharmacologically effective agent is timolol. 
betaxolol, levobunaloa, pilocarpine, and the antibiotics and 
corticosteriods disclosed for topical applications. 
0084. The composition and form of pharmaceutical prepa 
rations comprising the polymers disclosed, in combination 
with a drug or other therapeutic agent, can vary according to 
the intended route of administration. 
0085 Orally administered preparations can be in the form 
of Solids, liquids, emulsions, Suspensions, or gels, or prefer 
ably in dosage unit form, for example as tablets or capsules. 
Tablets can be compounded in combination with other ingre 
dients customarily used. Such as tale, vegetable oils, polyols, 
gums, gelatin, starch, and other carriers. The cationic poly 
mers can be dispersed in or combined with a suitable liquid 
carrier in Solutions, Suspensions, or emulsions. 
I0086 Parenteral compositions intended for injection, 
either Subcutaneously, intramuscularly, or intravenously, can 
be prepared as liquids or solid forms for Solution in liquid 
prior to injection, or as emulsions. Such preparations are 
sterile, and liquids to be injected intravenously should be 
isotonic. Suitable excipients are, for example, water, dex 
trose, Saline, and glycerol. 
0087 Administration of pharmaceutically acceptable 
salts of the substances described herein is included within the 
Scope of the invention. Such salts can be prepared from phar 
maceutically acceptable non-toxic bases including organic 
bases and inorganic bases. Salts derived from inorganic bases 
include Sodium, potassium, lithium, ammonium, calcium, 
magnesium, and the like. Salts derived from pharmaceuti 
cally acceptable organic non-toxic bases include salts of pri 
mary, secondary, and tertiary amines, basic amino acids, and 
the like. For a helpful discussion of pharmaceutical salts, see 
S. M. Berge et al., Journal of Pharmaceutical Sciences 66:1- 
19 (1977) the disclosure of which is hereby incorporated by 
reference. 
0088 Substances for injection, a preferred route of deliv 
ery, can be prepared in unit dosage form in ampules, or in 
multidose containers. The substances to be delivered can be 
present in Such forms as Suspensions, solutions, or emulsions 
in oily or preferably aqueous vehicles. Alternatively, the salt 
of the substance can be in lyophilized form for reconstitution, 
at the time of delivery, with a suitable vehicle, such as sterile 
pyrogen-free water. Both liquids as well as lyophilized forms 
that are to be reconstituted will comprise agents, preferably 
buffers, in amounts necessary to suitably adjust the pH of the 
injected Solution. For any parenteral use, particularly if the 
formulation is to be administered intravenously, the total 
concentration of solutes should be controlled to make the 
preparation isotonic, hypotonic, or weakly hypertonic. Non 
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ionic materials, such as Sugars, are preferred for adjusting 
tonicity, and Sucrose is particularly preferred. Any of these 
forms can further comprise Suitable formulatory agents. Such 
as starch or Sugar, glycerol or saline. The compositions per 
unit dosage, whether liquid or Solid, can contain from 0.1% to 
99% of polynucleotide material. 
I0089 Also disclosed are kits comprising the polymers and 
the substance to be delivered into the cell. The kits can com 
prise one or more packaged unit doses of a composition 
comprising the polymer and the Substance to be delivered into 
the cell. The units dosage ampules or multidose containers, in 
which the polymer and the substance to be delivered are 
packaged prior to use, can comprise an hermetically sealed 
container enclosing an amount of polynucleotide or Solution 
containing a Substance Suitable for a pharmaceutically effec 
tive dose thereof, or multiples of an effective dose. The poly 
mer and Substance can be packaged as a sterile formulation, 
and the hermetically sealed container is designed to preserve 
sterility of the formulation until use. 
0090 The disclosed polymers can also be present in liq 
uids, emulsions, or Suspensions for delivery of active thera 
peutic agents in aerosol form to cavities of the body Such as 
the nose, throat, or bronchial passages. The ratio of active 
ingredient to the polymer and the other compounding agents 
in these preparations will vary as the dosage form requires. 
0091. Depending on the intended mode of administration, 
the pharmaceutical compositions can be in the form of Solid, 
semi-solid or liquid dosage forms. Such as, for example, tab 
lets, Suppositories, pills, capsules, powders, liquids, Suspen 
sions, lotions, creams, gels, or the like, preferably in unit 
dosage form suitable for single administration of a precise 
dosage. The compositions will include, as noted above, an 
effective amount of the selected lipocomplex in combination 
with a pharmaceutically acceptable carrier and, in addition, 
can include other medicinal agents, pharmaceutical agents, 
carriers, adjuvants, diluents, etc. 
0092. For solid compositions, conventional nontoxic solid 
carriers include, for example, pharmaceutical grades of man 
nitol, lactose, starch, magnesium Stearate, Sodium saccharin, 
talc, cellulose, glucose, Sucrose, magnesium carbonate, and 
the like. Liquid pharmaceutically administrable composi 
tions can, for example, be prepared by dissolving, dispersing, 
etc., an active compound as described herein and optional 
pharmaceutical adjuvants in an excipient, Such as, for 
example, water, Saline aqueous dextrose, glycerol, ethanol, 
and the like, to thereby form a solution or suspension. If 
desired, the pharmaceutical composition to be administered 
can also contain minor amounts of nontoxic auxiliary Sub 
stances such as wetting or emulsifying agents, pH buffering 
agents and the like, for example, Sodium acetate, Sorbitan 
monolaurate, triethanolamine Sodium acetate, triethanola 
mine oleate, etc. Actual methods of preparing such dosage 
forms are known, or will be apparent, to those skilled in this 
art; for example see Remington's Pharmaceutical Sciences, 
referenced above. 
0093 Parental administration, if used, is generally char 
acterized by injection. Injectables can be prepared in conven 
tional forms, either as liquid solutions or Suspensions, Solid 
forms suitable for Solution or Suspension in liquid prior to 
injection, or as emulsions. A more recently revised approach 
for parental administration involves use of a slow release or 
Sustained release system, Such that a constant level of dosage 
is maintained. See, e.g., U.S. Pat. No. 3,710,795, which is 
incorporated by reference herein. 
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0094. When the polymers and substances to be delivered 
into a cell are used in Subjects, the Subject can be a vertebrate, 
Such as a mammal, a fish, a bird, a reptile, or an amphibian. 
Thus, the subject of the herein disclosed methods can be a 
human, non-human primate, horse, pig, rabbit, dog, sheep, 
goat, cow, cat, guinea pig or rodent. The term does not denote 
a particular age or sex. Thus, adult and newborn Subjects, as 
well as fetuses, whether male or female, are intended to be 
covered. A patient refers to a subject afflicted with a disease or 
disorder. The term “patient' includes human and veterinary 
Subjects. 
EXAMPLES 
0095. The following examples are put forth so as to pro 
vide those of ordinary skill in the art with a complete disclo 
Sure and description of how the compounds, compositions, 
articles, devices and/or methods claimed herein are made and 
evaluated, and are intended to be purely exemplary of the 
invention and are not intended to limit the scope of what the 
inventors regard as their invention. Efforts have been made to 
ensure accuracy with respect to numbers (e.g., amounts, tem 
perature, etc.), but some errors and deviations should be 
accounted for. Unless indicated otherwise, parts are parts by 
weight, temperature is in C. or is at ambient temperature, 
and pressure is at or near atmospheric. Data are reported as 
meantone standard deviation of independent replicate 
experiments. Statistical significance was determined for a 
given polymer using the unpaired Student's t-test. 
Example 1 
Synthesis of Cationic Polymers 
0096 Eight diepoxides, 1,4 butanediol diglycidyl ether 
(1.4 B), 1,4-cyclohexanedimethanol diglycidyl ether (14C), 
4-vinylcyclohexene diepoxide (4VCD), ethyleneglycol dig 
lycidyl ether (EDGE), glycerol diglycidyl ether (GDE), neo 
pentylglycol diglycidyl ether (NPDGE), poly(ethylenegly 
col) diglycidyl ether (PEGDE), and poly(propyleneglycol) 
diglycidyl ether (PPGDE) were purchased from Sigma-Ald 
rich and were used without any further purification. Ten 
amines, 1-(2-aminoethyl)piperidine, 1,4-bis(3-aminopropyl) 
piperazine, (1.4 Bis), 3,3'-diamino-N-methyl dipropylamine 
(3.3"), 4,7,10-trioxa-1,13-tridecanediamine, aniline, buty 
lamine, diethylenetriamine (DT), ethylenediamine (ED), 
N-(2-amino ethyl)-1,3-propanediamine (N-2amino), and 
pentaethylenehexamine were also purchased from Sigma 
Aldrich and used as received. 
0097 FIG. 1a shows the general reaction scheme 
employed for the generation of the library of eighty cationic 
polymers. FIG. 1b and FIG. 1c show monomers used in 
developing the combinatorial matrix of the polymer library. 
The eight diglycidyl ethers (2.3 mmol) were reacted with 
equimolar amounts of the amines; neat as-purchased solu 
tions were employed for both reactants. In the case of penta 
ethylenehexamine, the low solubility of the resulting poly 
mers at a 1:1 ratio of diglycidyl ether to amine necessitated 
the use of a 10:1 diglycidyl ether:amine molar ratio in subse 
quent experiments. The polymerization was carried out in 20 
mL glass scintillation vials for 16 h. After 16 h, the resulting 
polymer was diluted to a concentration of 2 mg/mL in 20 mM 
Tris buffer, pH 7.4. The solution pH was adjusted to 7.4 using 
30% hydrochloric acid in de-ionized (DI) water to compen 
sate for the alkalinity of the polymers. Polymers that were 
soluble at a concentration of 2 mg/mL at pH 7.4 were evalu 
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ated for their DNA-binding efficacies. Sixteen out of the 
eighty polymers synthesized were not soluble at concentra 
tions of 2 mg/ml. Sixty-four soluble polymers were employed 
in the primary Screening which involved an evaluation of their 
respective DNA-binding efficacies using the ethidium bro 
mide displacement assay. 
Example 2 
Screening of DNA-Binding Activity 
0098. An ethidium bromide displacement assay was 
employed to evaluate the DNA-binding affinity of the cat 
ionic polymer library in parallel. 1.5 mL of 6 g/mL double 
stranded, calf-thymus DNA was equilibrated with 15 uL of 
0.5 mg/mL ethidium bromide (all solutions were prepared in 
20 mM Tris buffer, pH 8.0). After equilibration, 25 L of 2 
mg/mL polymer was added to the DNA-ethidium bromide 
mixture and equilibrated for 20 minutes. 150 uL of the poly 
mer-DNA solution was transferred into a 96-well microtiter 
plate and the fluorescence (excitation at 260 nm, emission at 
595 nm) was measured using a plate reader (Perkin Elmer 
Lambda 6.0). The decrease in fluorescence intensity (percent 
fluorescence decreased compared to control) was used to rank 
DNA-binding efficacies of individual polymers. FIG.2 shows 
the DNA-binding efficacy of the cationic polymer library 
determined using the ethidium bromide displacement assay. 
As expected, polymers based on monoamines (e.g., aniline 
and butylamine) demonstrated low values of percent fluores 
cent decreased (i.e., low DNA-binding efficacies) while those 
derived from higher homologue polyamines, such as 1,4-Bis 
(3-aminopropyl)piperazine, 3,3'-diamino-N-methyl dipropy 
lamine, diethylenetriamine, and N-(2-aminoethyl)-1,3-pro 
panediamine demonstrated higher efficacies. Seven 
representative polymer leads, with different DNA binding 
efficacies (percent fluorescence decreased values ranging 
from 30% to 60%), were chosen for the transfection of PC3 
PSMA cells as described below. The following references 
describe the ethinium bromide displacement assay in detail: 
Boger, D. L.; Fink, B. E.; Brunette, S. R.: Tse, W.C.; Hedrick, 
M. P. A simple, high-resolution method for establishing DNA 
binding affinity and sequence selectivity. Journal of the 
American Chemical Society 2001, 123 (25), 5878-91; Geall, 
A. J.; Blagbrough, I. S. Rapid and sensitive ethidium bromide 
fluorescence quenching assay of polyamine conjugate-DNA 
interactions for the analysis of lipoplex formation in gene 
therapy. Journal of Pharmaceutical and Biomedical Analysis 
2000, 22 (5),849-59; Rege, K. Hu, S.; Moore, J. A.; Dordick, 
J. S.; Cramer, S. M. Chemoenzymatic synthesis and high 
throughput screening of an aminoglycoside-polyamine 
library: identification of high-affinity displacers and DNA 
binding ligands. Journal of the American Chemical Society 
2004, 126 (39), 12306-15; Rege, K.; Ladiwala, A.; Hu, S.: 
Breneman, C.M.; Dordick, J.S.: Cramer, S.M. Investigation 
of DNA-binding properties of an aminoglycoside-polyamine 
library using quantitative structure activity relationship 
(QSAR) models Journal of Chemical Information and Mod 
eling 2005, 45 (6), 1854-63; each of which is incorporated 
herein by this reference for teachings of the ethinium bromide 
displacement assay. 
Example 3 
Cationic Polymer-Mediated Transfection 
(0099. The pGL3 control vector (Promega Corp., Madison, 
Wis., U.S.A.), which encodes for the modified firefly 
US 2012/0196923 A1 
luciferase protein under the control of an SV40 promoter, was 
used in transfection experiments. The PC3-PSMA human 
prostate cancer cell line was provided by Dr. Michel Sadelain 
of the Memorial Sloan Cancer Center, New York, N.Y., U.S. 
A. The cells were cultured in a 5% CO, incubator at 37° C. 
using RPMI-1640 medium containing 10% heat-inactivated 
fetal bovine serum (FBS) and 1% antibiotics (10,000 units/ 
mL penicillin G/10,000 ug/mL streptomycin). MC3T3 
murine osteoblasts were cultured in a 5% CO incubator in 
Dulbecco's Modified Eagle's Medium (DMEM; BioWhit 
taker(R) containing 4.5 g/L glucose and L-glutamine, Supple 
mented with 10% fetal bovine serum (Invitrogen, Calif., U.S. 
A.) and 1% penicillin/streptomycin (Invitrogen, Calif., U.S. 
A.). PC3-PSMA and MC3T3 cells were seeded in 24-well 
plates at a density of 50,000 cells/well and allowed to attach 
overnight. Polymer pGL3 control plasmid at weight ratios of 
25:1 (polymer concentration 10 ng/uL and 200 ng pCL3 
plasmid in each well) were incubated for 30 minutes at room 
temperature and the resulting polyplexes were added to cells 
for 6 h either in the absence or presence of serum (10% FBS), 
at the end of which, fresh serum-containing medium was 
added to the cells. Following further incubation for 48 h, cells 
were lysed using the Bright Glo kit (Promega) and analyzed 
for luciferase protein expression (in relative luminescence 
units or RLU) using a plate reader (Bio-Tek Synergy 2). The 
protein content in each well was determined using the BCA 
assay and the luminescence value (RLU) was normalized by 
the protein content. Transfection efficacies of different poly 
mers from the library were compared with the normalized 
value (RLU/mg protein) obtained for pBI-25. 
0100 FIG. 3a shows the transfection of PC3-PSMA cells 
with the pGL3 plasmid using a set of lead polymers selected 
from the DNA-binding screen. Representative polymer leads 
that possessed moderate (30% fluorescence decreased) to 
high (>60% fluorescence decreased) DNA binding efficacies 
were employed in the transfection experiments. Calf-thymus 
DNA was used only as generic double-stranded DNA in the 
primary DNA binding screen for identifying lead polymers. 
However, the lack of a constitutive promoter region in calf 
thymus DNA implies that this DNA cannot be employed as a 
reporter for transfection. Consequently, transfections were 
carried out with the pGL3 control vector which codes for 
luciferase protein. A polymer to plasmid ratio of 25:1 was 
employed in order to evaluate the transfection efficacies of the 
selected polymers. The use of nitrogen: phosphorus (N:P) 
ratio is common in comparing cationic lipid and cationic 
polymer meditated gene delivery. However, a w/w ratio was 
used, which has been previously employed for evaluating 
polymeric transfection agents. 
0101. In order to evaluate polymer-mediated transfection 
efficacy, luminescence (relative luminescence units or RLU) 
due to the expression of the luciferase protein was normalized 
to the protein content in each well, and the normalized values 
were compared to those determined for pBI-25. A number of 
polymers demonstrated Statistically significant higher trans 
fection efficacies than pRI-25 in the absence of serum. In 
particular, the 1,4C-1,4-Bispolymer, based on the monomers, 
1,4-cyclohexanedimethanol diglycidyl ether (14C) and 1,4- 
bis(3-aminopropyl)piperazine, (1.4 Bis).demonstrated 
greatly (>80-fold) higher transfection efficacy than pEI-25 in 
the absence of serum. Other polymers demonstrated moder 
ately higher (4-8 fold) or comparable transfection efficacies 
compared to that of pEI-25 in the absence of serum. For 
example, Neopentylglycol diglycidyl ether-1,4-bis(3-amino 
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propyl)piperazine (NPGDE-14 Bis) and Ethylene glycol 
diglycidyl ether-1,4-bis(3-aminopropyl)piperazine (EGDE 
1.4 Bis) polymers demonstrated approximately eight-fold 
higher efficacies than pEI-25. Polymers generated using 1,4- 
bis(3-aminopropyl)piperazine (1.4 Bis) as the amine mono 
mer resulted in candidates with higher gene transfection effi 
cacies than pRI-25. 
0102 The transfection efficacy of the 1.4 C-14Bis poly 
mer was further evaluated as a function of polymer dose (i.e. 
polymer:pCL3 plasmid) in the absence of serum (FIG. 3b). 
While the polymer demonstrated comparable transfection 
efficacies to that ofpl. I-25 at low polymer: plasmid ratios (1:1 
and 5:1), transfection efficacies with higher polymer ratios 
(10:1, 20:1 and 25:1) were significantly higher than those for 
pEI-25. In addition to the normalized ratios presented in FIG. 
3b, the actual protein expression values (i.e. RLU/mg) were 
the highest observed in the experiments (not shown) when the 
14C-1.4 Bis polymer was used, indicating that the polymer 
resulted in greater protein expression than pEI-25 under all 
conditions evaluated. 
0103) A sub-set of polymers that demonstrated appre 
ciable transfection efficacies in the absence of serum was 
employed to transfect PC3-PSMA cells in the presence of 
serum-containing media. In the presence of serum, the trans 
fection efficacy dropped in all polymers evaluated. Neverthe 
less, the 1.4 C-14 Bis polymer demonstrated considerably 
higher efficacies (approximately 30-fold) compared to pEI 
25 in the presence of serum (FIG. 3c). The transfection effi 
cacies of other polymers investigated were not statistically 
different compared to that of pEI-25. 
0.104 Transfections were also carried out in serum-con 
taining media with murine osteoblasts in order to compare the 
efficacy of the 14C-1,4 Bis polymer to that of pEI-25 in cells 
unrelated to human prostate cancer cells. Lower transfection 
efficacies were observed in the MC3T3 murine osteoblast cell 
line for both polymers (not shown) as compared to PC3 
PSMA cells, reflecting the challenges of transfecting these 
cells with non-viral transfection agents. However, as with the 
PC3-PSMA cells, the 14 C-14 Bis polymer was more effec 
tive (approximately 23-fold) than pEI-25 in transfecting these 
cells (FIG.3d), indicating that the polymer might be useful in 
transfecting different cell types. 
Example 4 
Determining Cytotoxity of Polymer and Polyplexes 
0105 PC3-PSMA cells were seeded in a 24-well plate at a 
density of 50,000 cells/well and incubated overnight at 37° C. 
Different weight ratios of polymer-DNA polyplexes (10:1, 
25:1, and 50:1 polymer: pGL3 plasmid) and different con 
centrations of polymers (4-20 ng/uL) were added in the 
absence of serum and the cells were incubated for 6 h to 
determine polyplex- and polymer-induced cytotoxicity, 
respectively. Following incubation, cells were treated with 
100 uL of 4 uMethidium homodimer-1 (EthD-1: Invitrogen) 
for 15 minutes and imaged immediately using Zeiss AXioOb 
server D1 inverted microscope (10x/0.3 numerical aperture 
(NA) objective: Carl Zeiss MicroImaging Inc., Germany). 
Fluorescence using excitation at 550 run and emission at 670 
nm were used for the microscopy; dead/dying cells with 
compromised nuclei stained positive (red) for EthD-1. 
0106 Quantitative analysis of polymer/polyplex induced 
cell death was carried out as follows. The number of dead 
cells in each case was counted manually for three individual 
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fields of fluorescence microscopy images by means of the 
Cell Counter plugin in Image.J software (Rasband, W. S., 
Image.J., U.S. National Institutes of Health, Bethesda, Md., 
USA, 1997-2005). The number of dead cells in both dead and 
live controls were determined for at least two fields of view 
and their average values were calculated. The number of red 
fluorescent cells in the case of each polymer or the corre 
sponding polyplex was determined, and the percentage of 
dead cells was calculated by normalizing the number of dead 
cells in the sample to number of dead cells in the dead control. 
0107. With reference to FIG.4, pEI-25 was significantly 
more cytotoxic when compared to the 14 C-14 Bis polymer 
at concentrations of 4 ng/uL and 10 ng/LL (equivalent poly 
mer: pGL3 plasmid ratios of 10:1 and 25:1). However, both 
polymers demonstrated similar cytotoxicities at 20 ng/ul 
(equivalent polymer: pGL3 plasmid ratios of 50:1). Interest 
ingly, 1.4 C-14 Bis polymer based polyplexes (polymer: 
pGL3 plasmid ratios of 10:1 and 25:1) demonstrated lower 
cytotoxicities when compared to the polymer alone. In con 
trast, pFI-25 based polyplexes showed comparable cytotox 
icity compared to the polymer alone at all polymer pGL3 
plasmid ratios investigated. The low cytotoxicities of the 
14C-14 Bis polymer and its polyplex with pGL3 plasmid are 
believed to be in part responsible for the higher transfection 
efficacies of this polymer. 
0108) Phase contrast and fluorescence microscopy images 
were used to demonstrate the cytotoxicity of pl’I-25 polymer, 
14C-14Bis polymer, pFI-25: pGL3 polyplex, and 14C-1, 
4Bis:pGL3 polyplex toward PC3-PSMA cells in serum-free 
media 
Example 5 
Characterization of (1,4C-14 Bis) 
0109 Characterization experiments were carried out with 
polymer (14C-14Bis) that demonstrated successful cellular 
transfection. The polymer EGDE-3.3" was also used in some 
cases in order to demonstrate the results for a different poly 
mer used in transfections. 
0110. The disappearance of reactive (primary and second 
ary) amines with time was used to monitor the kinetics of the 
diglycidyl ether-polyamine reaction (FIG.1a); the ninhydrin 
assay (Friedman, M. Applications of the ninhydrin reaction 
for analysis of amino acids, peptides, and proteins to agricul 
tural and biomedical Sciences. Journal of Agricultural and 
Food Chemistry 2004, 52 (3),385-406.60) was used to deter 
mine the concentration of reactive amines at each time point. 
The ninhydrin assay results in a yellow-orange color in the 
case of secondary amines and a dark blue/purple color in the 
case of primary amines. Approximately 2 mg of the polymers 
were weighed into 1.5 mL microcentrifuge tubes (Fisher) at 
different time points (0-24 h) during the polymerization reac 
tion. Ninhydrin reagent (Sigma; 100 uL) and DI water (200 
uL) were added to the polymers in the centrifuge tubes, fol 
lowing which the tubes were placed in a boiling water bath for 
10 min and cooled to room temperature (22°C.). The mixture 
was diluted by adding 500 uL of 95% ethanol. The mixtures 
were further diluted 10- and 100-fold using DI water in order 
to obtain absorbance values within the calibration range (us 
ing glycine standards) employed. Absorbance was measured 
at 570 nm in triplicate for each sample using a microplate 
reader (BioTek Synergy 2). The amine concentration was 
monitored every 4 h, and the concentration of amines in the 
reaction mixture at a given time point was normalized with 
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the concentration of amines at the start of the reaction (t=0) in 
order to obtain percentage amine values. 
0111. The amine concentration remained largely invariant 
after 12 h of reaction time as determined from the using 
absorbance spectroscopy based on the formation of dark blue/ 
purple color following reaction with primary amines. These 
results indicate that a reaction time of 16h was appropriate for 
the generation of polymers that demonstrated moderate to 
high DNA binding and cellular transfection efficacies. In 
addition, the presence of residual primary amines (approxi 
mately 30% of the initial primary amine concentration, as 
reported by the dark blue color of the ninhydrin reaction), 
indicated the formation of branched polymers with multiple 
terminal primary amines. This was consistent with what can 
be expected from the employed reaction chemistry (FIG.1a). 
0112 Gel permeation chromatography was employed to 
determine molecular weight values of the 14C-1,4-Bis poly 
mer which were as follows: Mn) 3.9 kDa and Mw) 23.5 kDa 
indicating a polydispersity (PD) of 5.96. These values indi 
cated that the polymer molecular weights were comparable to 
those of pl’I-25 used in the study: Mn) 10 kDa, Mw) 25 kDa, 
PD) 2.5 (Sigma). Polymer molecular weight was determined 
using a ViscoGEL column (MBLMW, Mixed Bed, dimen 
sions: 7.8 mm x 30 cm) using 5% (v/v) acetic acid in water as 
the eluent (flow rate 1 mL/min) (Joshi, A.; Saraph, A.; Poon, 
V.; Mogridge, J.; Kane, R. S. Synthesis of potent inhibitors of 
anthrax toxin based on poly-Lglutamic acid. Bioconjugate 
Chem. 2006, 17 (5), 1265-1269.) The Mn and Mw values 
were estimated as an average of two experimental runs using 
a light scattering Viscotek 270 Trisec Dual Detector; 
OmniSEC software, ) 670 nm. 
0113 Formation of the 14C-14Bis polymer was further 
verified using Fourier transform infrared (FT-IR) spectros 
copy by following the appearance and disappearance of cer 
tain bands as a function of reaction time. FT-IR spectra were 
obtained at two different polymerization time points (t=0 and 
t=16 h) in order to ascertain the formation of the polymers. 
Polymer samples were loaded on a germanium attenuated 
total reflectance (GATR) crystal such that they covered the 
center area of the crystal. The sample chamber was equili 
brated to approximately 4 mbar pressure in order to minimize 
interference from atmospheric moisture and CO. The 
absorption spectrum was measured between 650 and 4,000 
cm-1 using a Broker IFS 66 V/S FT-IR spectrometer and the 
background spectrum was subtracted from all sample spectra. 
I0114. The epoxide peak ranging from 858 to 918 cm can 
be seen in the monomer mixture at time t-Oh (FIG.5b) due to 
stretching and contraction of C-O bonds in the epoxide 
moiety. However, this peak is significantly reduced after 16 h 
of reaction time, indicating a reduction in the epoxide content 
upon formation of the cationic polymer (Loos, M. R.: Coelho, 
L. A. F.; Pezzin, S. H.; Amico, S. C. The effect of acetone 
addition on the properties of epoxy. Polimeros: Ciencia e 
Tecnologia 2008, 18 (1), 76-80). Characteristic spectral 
bands of primary amines were seen at 1100-1128 and 3358 
3382 cm due to the presence of C N and N-H bonds, 
respectively. The broadbands from 3382-3402 cm upon 16 
h of reaction time can be attributed to hydroxyl (—OH) 
groups generated upon reaction of the epoxy rings with pri 
mary and secondary amines. Taken together, FT-IR analysis 
further confirmed that the diglycidyl ether-polyamine reac 
tion resulted in the formation of the 14C-14Bis polymer that 
demonstrated high transfection efficacies in vitro. 
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What is claimed is: 
1. A composition, comprising, a polymer of a diepoxide 
and an amine, wherein the diepoxide is 
a. 14butanediol diglycidyl ether (14 B); 
b. 1.4-cyclohexanedimethanol diglycidyl ether (14C); 
c. 4-vinylcyclohexene diepoxide (4VCD); 
d. ethyleneglycol diglycidyl ether (EDGE): 
e.glycerol diglycidyl ether (GDE); 
f. neopentylglycol diglycidyl ether (NPDGE): 
g. poly(ethyleneglycol) diglycidyl ether (PEGDE); or 
h. poly(propyleneglycol) diglycidyl ether (PPGDE); and 
wherein the amine is 
i. 1-(2-aminoethyl)piperidine; 
j. 1,4-bis(3-aminopropyl)piperazine (1.4 Bis); 




o. diethylenetriamine (DT); 
p. ethylenediamine (ED); 
q. N-(2-aminoethyl)-1,3-propanediamine (N-2amino); or 
r. pentaethylenehexamine. 
2. The composition of claim 1, wherein the polymer has a 
number average molecular weight (Mn) of from about 1 to 
about 20 kDa. 
3. The composition of claim 1, wherein the polymer has a 
weight average molecular weight (Mw) of from about 10 to 
about 50 kDa. 
4. The composition of claim 1, wherein the polymer has a 
polydispersity index (PDI) of from about 2 to about 7. 
5. The composition of claim 1, wherein the polymer is 
cationic. 
6. The composition of claim 1, further comprising a Sub 
stance to be delivered into a cell. 
7. The composition of claim 6, wherein the substance is a 
nucleic acid. 
8. The composition of claim 1, wherein the polymer is 
poly(ethyleneglycol diglycidyl ether)-co-(3,3'-diamino-N- 
methyl dipropylamine) or poly(1,4-cyclohexanedimethanol 
diglycidyl ether)-co-1,4-bis(3-aminopropyl)piperazine. 
9. A pharmaceutical composition, comprising, a polymer 
of a diepoxide and an amine, wherein the diepoxide is 
a. 14butanediol diglycidyl ether (14 B); 
b. 1.4-cyclohexanedimethanol diglycidyl ether (14C); 
c. 4-vinylcyclohexene diepoxide (4VCD); 
d. ethyleneglycol diglycidyl ether (EDGE): 
e.glycerol diglycidyl ether (GDE); 
f. neopentylglycol diglycidyl ether (NPDGE): 
g. poly(ethyleneglycol) diglycidyl ether (PEGDE); or 
h. poly(propyleneglycol) diglycidyl ether (PPGDE); and 
wherein the amine is 
i. 1-(2-aminoethyl)piperidine; 
j. 1,4-bis(3-aminopropyl)piperazine (1.4 Bis); 
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o. diethylenetriamine (DT); 
p. ethylenediamine (ED); 
N-(2-aminoethyl)-1,3-propanediamine (N-2amino); or 
r. pentaethylenehexamine; and 
and a substance to be delivered into a cell. 
10. The pharmaceutical composition of claim 9, wherein 
the polymer has a number average molecular weight (Mn) of 
from about 1 to about 20 kDa. 
11. The pharmaceutical composition of claim 9, wherein 
the polymer has a weight average molecular weight (Mw) of 
from about 10 to about 50 kDa. 
12. The pharmaceutical composition of claim 9, wherein 
the polymer has a polydispersity index (PDI) of from about 2 
to about 7. 
13. The pharmaceutical composition of claim 9, wherein 
the polymer is cationic. 
14. The pharmaceutical composition of claim 9, wherein 
the Substance is a nucleic acid. 
15. A method for delivering a nucleic acid into a cell, 
comprising, contacting a cell withi.) a polymer of a diepoxide 
and an amine; and ii.) a nucleic acid; 
wherein the diepoxide is 
a. 14butanediol diglycidyl ether (14 B); 
b. 1.4-cyclohexanedimethanol diglycidyl ether (14C); 
c. 4-vinylcyclohexene diepoxide (4VCD); 
d. ethyleneglycol diglycidyl ether (EDGE): 
e.glycerol diglycidyl ether (GDE); 
f. neopentylglycol diglycidyl ether (NPDGE): 
g. poly(ethyleneglycol) diglycidyl ether (PEGDE); or 
h. poly(propyleneglycol) diglycidyl ether (PPGDE): 
and 
wherein the amine is 
i. 1-(2-aminoethyl)piperidine; 
j. 1,4-bis(3-aminopropyl)piperazine (1.4 Bis); 




o. diethylenetriamine (DT); 
p. ethylenediamine (ED); 
q. N-(2-aminoethyl)-1,3-propanediamine (N-2amino); 
O 
r. pentaethylenehexamine. 
16. The method of claim 15, wherein the polymer has a 
weight average molecular weight (Mw) of from about 10 to 
about 50 kDa. 
17. The method of claim 15, wherein the polymer has a 
polydispersity index (PDI) of from about 2 to about 7. 
18. The method of claim 15, wherein the polymer is cat 
ionic. 
19. The method of claim 15, wherein the polymer is poly 
(ethyleneglycol diglycidyl ether)-co-(3,3'-diamino-N-me 
thyl dipropylamine) or poly(1,4-cyclohexanedimethanol dig 
lycidyl ether)-co-1,4-bis(3-aminopropyl)piperazine. 
20. The method of claim 15, wherein the polymer and the 
nucleic acid together form a polyplex. 
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